Clinical application of gene expression signature as a predictor of recurrence in colorectal cancer

基因表达特征作为结直肠癌复发预测因子的临床应用

• 批准号: 23591962
• 负责人: TAKEMASA Ichiro
• 金额: $ 3.24万
• 依托单位: Osaka University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2011
• 资助国家: 日本
• 起止时间: 2011 至 2013
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-23591962/
• 关键词: 大腸癌; 予後・治療応答性; 予測診断; 臨床応用; パスウェイ; 大腸がん; 遺伝子発現プロファイル; 予後予測; 個別化医療; 予後診断用臨床チップ; 癌の多様性; 薬剤感受性

We have been attempting to stratify curatively resected colorectal cancer(CRC) into good or poor prognoses based on gene expression signatures.Using the clinical DNA chip,we attempted to select discriminator genes,with the 150 retrospective CRC sample set,resulting 55 markers.We then applied the discriminator set to the second,150 CRC samples set in a prospective sample set for predictive accuracy and prognostic validity.Kaplan-Meyer analysis showed a significant difference between the"good signature group(low-risk)"and the "poor signature group (high risk)" (Log-rank p equal 0.0019).The multivariate Cox analyses showed the significant parameters to predict the prognosis with a hazard ratio of 3.5(95 persent confidence interval, 0.12-0.67 p=0.004). this personalized prognosis is crucial with CRC patients, the predictive performance may deserve serious consideration for possible application to clinic.

We have been attempting to stratify curatively resected colorectal cancer(CRC) into good or poor prognoses based on gene expression signatures.Using the clinical DNA chip,we attempted to select discriminator genes,with the 150 retrospective CRC sample set,resulting 55 markers.We then applied the discriminator set to the second,150 CRC samples set in a prospective sample set for predictive accuracy and prognostic validity.Kaplan-Meyer analysis showed a significant difference between the"good signature group(low-risk)"and the "poor signature group (high risk)" (Log-rank p equal 0.0019).The multivariate Cox analyses showed the significant parameters to predict the prognosis with a hazard ratio of 3.5(95 persent confidence interval, 0.12-0.67 p=0.004).这种个性化的预后对CRC患者至关重要，预测性能值得认真考虑到可能应用诊所。

项目成果

大腸癌リンパ節転移におけるOSNA法を用いた新たな分子生物学的検査法の意義

OSNA方法新的分子生物学检测结直肠癌淋巴结转移的意义

• 作者: 宮崎進;山本浩文;賀川義規;鈴木陽三;竹政伊知朗;水島恒和;池田正孝;関本貢嗣;松浦成昭;土岐祐一郎;森正樹
• 通讯作者: 森正樹